We’ve all heard the phrase “what a difference a day makes.” That couldn’t be more accurate for someone with vasculitis or any other chronic disease. Some days can feel as if they last for weeks or months, or never seem to end. Other days fly by in a minute. For…
The U.S. Patent and Trademark Office (USPTO) has granted Conduit Pharmaceuticals a patent for AZD1656, its experimental therapy for ANCA-associated vasculitis (AAV) and other autoimmune diseases. The USPTO granted a composition of matter patent, which is a type of patent that relates to novel compounds made from two or…
Long-term treatment with Nucala (mepolizumab) — approved for use in EGPA, or eosinophilic granulomatosis with polyangiitis, the rarest type of ANCA-associated vasculitis — appears to be well tolerated by most patients, and was seen to reduce or even eliminate corticosteroid use. That’s according to new data from an…
Adding Tavneos (avacopan) to standard treatment is as safe and effective in older people with ANCA-associated vasculitis (AAV) as it is among younger patients, according to the findings of a post-hoc analysis of clinical trial data. The approved oral therapy “showed similar efficacy and safety results in patients…
Disease symptoms among people with ANCA-associated vasculitis (AAV) were found to vary by age at diagnosis and biological sex, according to data from more than 1,100 Scandinavian patients. “We identified significant differences in clinical presentation of the disease between female and male patients and between patients with a young…
It’s hard not to compare ourselves with other people living with ANCA vasculitis who have benefited from medications and treatments. Comparing is human nature — and the cause of much suffering. It’s particularly hard when we’re experiencing a flare or side effects of our tough medication regimens. Seeing people…
A Phase 1 clinical trial assessing SC291, an experimental CAR T-cell therapy that Sana Biotechnology is developing for ANCA-associated vasculitis (AAV) and other autoimmune diseases, is recruiting patients at a number of sites across the U.S. Called GLEAM (NCT06294236), the study started enrolling up to…
A higher risk of death among AAV patients with interstitial lung disease (ILD) is significantly associated with older age, episodes of sudden symptom worsening, and microscopic polyangiitis (MPA), a common type of anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV). That’s according to a review of published studies that also pointed…
This February marked four years since the day my world — our world — changed forever. For the previous 11 months, my wife, Pam Squires, and I had been stuck in a relentless loop, a medical maze with no clear answers. Fifty-seven different trips to the hospital or doctor’s office.
Rita Martins is a dedicated clinical pharmacist with extensive experience in primary care and hospital settings. Passionate about patient-centered care, she empowers patients and caregivers through education, ensuring they are actively involved in their treatment journey. With a strong commitment to fostering engagement and delivering high-quality care, Rita strives to…
Get regular updates to your inbox.